<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04858191</url>
  </required_header>
  <id_info>
    <org_study_id>1000068639</org_study_id>
    <nct_id>NCT04858191</nct_id>
  </id_info>
  <brief_title>Utilizing Hyperpolarized 129Xe Magnetic Resonance Imaging in Children With Primary Ciliary Dyskinesia</brief_title>
  <acronym>PCD MRI</acronym>
  <official_title>Utilizing Hyperpolarized 129Xe Magnetic Resonance Imaging in Children With Primary Ciliary Dyskinesia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Hospital for Sick Children</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Provincial Health Services Authority</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The Hospital for Sick Children</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study investigates the use of hyperpolarized 129Xe magnetic resonance imaging (MRI) in&#xD;
      children with primary ciliary dyskinesia (PCD) in detecting ventilation defects. The&#xD;
      investigators will establish the feasibility and reliability of this test and how it changes&#xD;
      compared to other pulmonary function tests.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Ciliary Dyskinesia (PCD) is an autosomal recessive inherited disorder caused by&#xD;
      defects in ciliary structure and/or function. Prevention or delaying disease progression&#xD;
      requires medical therapies and routine lung function monitoring, with the goal of early&#xD;
      initiation of medical therapies. Of course, this is contingent on recognizing early lung&#xD;
      disease.&#xD;
&#xD;
      Current investigations for monitoring lung disease include pulmonary function tests (PFT),&#xD;
      chest x rays and chest CTs. But each of these modalities are either not sensitive enough or&#xD;
      expose the patient to ionizing radiation.&#xD;
&#xD;
      The investigators believe that hyperpolarized 129Xe MRI (HP Xe-MRI), new imaging modality,&#xD;
      will be more sensitive then current tests and also avoid the need for ionizing radiation. To&#xD;
      evaluate this, The investigators will compare HP Xe-MRI to PFT, when the patient is well and&#xD;
      during a pulmonary exacerbation that is being treated.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Ventilation Defect Percentage (VDP)</measure>
    <time_frame>Within 1 year of study initiation</time_frame>
    <description>Reliability; initial test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ventilation Defect Percentage (VDP)</measure>
    <time_frame>Within 1 week of initial test</time_frame>
    <description>Reliability; re-test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ventilation Defect Percentage (VDP)</measure>
    <time_frame>Within 48 hours of pulmonary exacerbation diagnosis</time_frame>
    <description>VDP within 48h of pulmonary exacerbation diagnosis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ventilation Defect Percentage (VDP)</measure>
    <time_frame>Within 48 hours of antibiotic completion</time_frame>
    <description>VDP within 48h of antibiotic completion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pulmonary function tests (PFTs)</measure>
    <time_frame>Within 1 year of study initiation</time_frame>
    <description>Reliability; initial test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary function tests (PFTs)</measure>
    <time_frame>Within 1 week of initial test</time_frame>
    <description>Reliability; re-test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary function tests (PFTs)</measure>
    <time_frame>Within 48 hours of pulmonary exacerbation diagnosis</time_frame>
    <description>PFT within 48h of pulmonary exaction diagnosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary function tests (PFTs)</measure>
    <time_frame>Within 48 hours of antibiotic completion</time_frame>
    <description>PFT within 48h of antibiotic completion</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Primary Ciliary Dyskinesia</condition>
  <arm_group>
    <arm_group_label>Pediatric PCD</arm_group_label>
    <description>Pediatric participants with PCD</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients aged 6-18 with primary ciliary dyskinesia&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Diagnosis of PCD as having either (i) biallelic mutations in known PCD genes or (ii)&#xD;
             classic transmission electron microscopy structural ciliary defect&#xD;
&#xD;
          -  Informed consent and verbal assent (as appropriate) provided by the participant's&#xD;
             parent or legal guardian and the participant&#xD;
&#xD;
          -  Ages 6-18 years and able to perform reproducible spirometry and achieve a breath hold&#xD;
             duration sufficient for MRI acquisition&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Any other cardiac or respiratory disease&#xD;
&#xD;
          -  Inability to perform a breath-hold of adequate duration for MRI acquisition&#xD;
&#xD;
          -  Medical instability that would preclude the ability to undergo the required&#xD;
             investigations&#xD;
&#xD;
          -  FEV1 % predicted &lt;40% on any PFT within last 2 months at time of consent&#xD;
&#xD;
          -  Use of supplementary oxygen&#xD;
&#xD;
          -  Severe claustrophobia&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
&#xD;
          -  Presence of metal implants or other MRI contraindications&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Felix Ratjen, MD, PhD, FRCP(C), FERS</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Hospital for Sick Children</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wallace Wee, MD</last_name>
    <phone>416-813-5587</phone>
    <email>wallace.wee@sickkids.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michael Sawras</last_name>
    <phone>416-813-5587</phone>
    <email>michael.sawras@sickkids.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Wallace Wee, MD</last_name>
      <phone>416-813-5587</phone>
      <email>wallace.wee@sickkids.ca</email>
    </contact>
    <contact_backup>
      <last_name>Michael Sawras</last_name>
      <phone>416-813-5587</phone>
    </contact_backup>
    <investigator>
      <last_name>Felix Ratjen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 25, 2021</study_first_submitted>
  <study_first_submitted_qc>April 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 26, 2021</study_first_posted>
  <last_update_submitted>September 20, 2021</last_update_submitted>
  <last_update_submitted_qc>September 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Hospital for Sick Children</investigator_affiliation>
    <investigator_full_name>Felix Ratjen</investigator_full_name>
    <investigator_title>Principle investigator</investigator_title>
  </responsible_party>
  <keyword>Xenon MRI</keyword>
  <keyword>Lung</keyword>
  <keyword>Pulmonary Exacerbation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ciliary Motility Disorders</mesh_term>
    <mesh_term>Dyskinesias</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data will be shared between two participating sites for this study. A data transfer agreement will be created and implemented to ensure smooth transfer of data</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>The data will be available after enrolling the first participant and will be available for the duration of the study.</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

